Skip to main content

Next-Generation Sequencing Technology to Identify Minimal Residual Disease in Lymphoid Malignancies

Part of the Methods in Molecular Biology book series (MIMB,volume 2185)

Abstract

Next-generation sequencing (NGS) of immunoglobulin (IG) and T cell receptor (TR) rearrangements represents a modern alternative to classical RQ-PCR-based minimal residual disease (MRD) detection. The same primer sets and conditions can be used for all patients, which is undoubtedly one of the most important benefits of NGS, not only reducing the labor required to perform the analysis but also enabling the assay to comply with the upcoming EU IVD regulation. So far, only one standardized academic protocol for this task has been published, developed, and validated within the EuroClonality-NGS working group. In this chapter we describe the materials and methods for amplicon library preparation for sequencing on Illumina MiSeq, and the bioinformatic pipeline for this protocol.

Key words

  • Next-generation sequencing
  • Minimal residual disease
  • Amplicon sequencing
  • Library preparation
  • Immunoglobulin
  • T cell receptor
  • Rearrangement
  • Bioinformatics

This is a preview of subscription content, access via your institution.

Buying options

Protocol
USD   49.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-1-0716-0810-4_7
  • Chapter length: 17 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   119.00
Price excludes VAT (USA)
  • ISBN: 978-1-0716-0810-4
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   159.99
Price excludes VAT (USA)
Hardcover Book
USD   219.99
Price excludes VAT (USA)
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. van der Velden VHJ, van Dongen JJM (2009) MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. In: Methods in molecular biology, Clifton, NJ, pp 115–150

    Google Scholar 

  2. van der Velden VHJ, Cazzaniga G, Schrauder A et al (2007) Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 21:604–611. https://doi.org/10.1038/sj.leu.2404586

    CAS  CrossRef  PubMed  Google Scholar 

  3. Gomez-Arteaga A, Guzman ML (2018) Minimal residual disease in acute myeloid leukemia. In: Advances in experimental medicine and biology. National Center for Biotechnology Information, Bethesda, MD, pp 111–125

    Google Scholar 

  4. Schuurhuis GJ, Heuser M, Freeman S et al (2018) Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 131:1275–1291. https://doi.org/10.1182/blood-2017-09-801498

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  5. Voso MT, Ottone T, Lavorgna S et al (2019) MRD in AML: the role of new techniques. Front Oncol 9:655. https://doi.org/10.3389/fonc.2019.00655

    CrossRef  PubMed  PubMed Central  Google Scholar 

  6. Steensma DP (2018) Clinical consequences of clonal hematopoiesis of indeterminate potential. Hematology 2018:264–269. https://doi.org/10.1182/asheducation-2018.1.264

    CrossRef  PubMed  PubMed Central  Google Scholar 

  7. Karner K, George TI, Patel JL (2019) Current aspects of clonal hematopoiesis: implications for clinical diagnosis. Ann Lab Med 39:509. https://doi.org/10.3343/alm.2019.39.6.509

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  8. Brüggemann M, Kotrová M, Knecht H et al (2019) Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia. 33(9):2241–2253. https://doi.org/10.1038/s41375-019-0496-7

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  9. Kotrova M, Muzikova K, Mejstrikova E et al (2015) The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL. Blood 126:1045. https://doi.org/10.1182/BLOOD-2015-07-655159

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  10. Faham M, Zheng J, Moorhead M et al (2012) Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 120:5173–5180. https://doi.org/10.1182/blood-2012-07-444042

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  11. Wu D, Sherwood A, Fromm JR et al (2012) High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med 4:134ra63–134ra63. https://doi.org/10.1126/scitranslmed.3003656

    CAS  CrossRef  PubMed  Google Scholar 

  12. Wu D, Emerson RO, Sherwood A et al (2014) Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. Clin Cancer Res 20:4540–4548. https://doi.org/10.1158/1078-0432.CCR-13-3231

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  13. Carlson CS, Emerson RO, Sherwood AM et al (2013) Using synthetic templates to design an unbiased multiplex PCR assay. Nat Commun 4:2680. https://doi.org/10.1038/ncomms3680

    CAS  CrossRef  PubMed  Google Scholar 

  14. Knecht H, Reigl T, Kotrová M et al (2019) Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. Leukemia 33(9):2254–2265. https://doi.org/10.1038/s41375-019-0499-4

    CrossRef  PubMed  PubMed Central  Google Scholar 

  15. Bystry V, Reigl T, Krejci A, et al (2016) ARResT/Interrogate: an interactive immunoprofiler for IG/TR NGS data. Bioinformatics 33:btw634. doi:https://doi.org/10.1093/bioinformaticsBioinformatics/btw634

Download references

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Monika Brüggemann .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2021 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Verify currency and authenticity via CrossMark

Cite this protocol

Kotrova, M., Darzentas, N., Pott, C., Brüggemann, M., On Behalf of the EuroClonality-NGS Working Group. (2021). Next-Generation Sequencing Technology to Identify Minimal Residual Disease in Lymphoid Malignancies. In: Cobaleda, C., Sánchez-García, I. (eds) Leukemia Stem Cells. Methods in Molecular Biology, vol 2185. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0810-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-0810-4_7

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-0809-8

  • Online ISBN: 978-1-0716-0810-4

  • eBook Packages: Springer Protocols